Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT04796324 Recruiting - Clinical trials for Metastatic Breast Cancer

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of an anthracycline and taxanes.

NCT ID: NCT04796220 Recruiting - Breast Cancer Clinical Trials

Focused Ultrasound and Gemcitabine in Breast Cancer

Breast 54
Start date: January 27, 2022
Phase: Phase 1
Study type: Interventional

This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We will be testing the effects of each of these regimens on cells in the immune system. We hypothesize that the combination of focused ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will increase T cell activity. We also hypothesize that focused ultrasound ablation and low-dose gemcitabine will be safe and will result in non-inferior surgical completion rates and tumor margin assessments.

NCT ID: NCT04795778 Recruiting - Breast Cancer Clinical Trials

The Validity and Reliability of FIT-HaNSA in Breast Cancer Patients

Start date: February 1, 2021
Phase:
Study type: Observational

Breast cancer is the most common type of cancer among women and covers 25% of all cancers. After mastectomy and reconstruction, many patients develop various upper extremity complications such as joint movement limitation, pain, lymphedema, and axillary cord. Because of such upper extremity problems, evaluation and treatment of upper extremity functions are important. Upper extremity functions are generally evaluated with questionnaires filled out by the patients themselves and which reflect their own perspectives subjectively. However, these questionnaires cannot reflect the observations and evaluations of the clinicians. Performance tests are important for clinicians to make decisions. With this study, we want to examine the usability of the FIT-HaNSA test in the evaluation of upper extremity functions in patients with breast cancer. Our hypothesis; The FıtHaNSA test is successful in evaluating the upper extremity function in patients with breast cancer.

NCT ID: NCT04795349 Recruiting - Breast Cancer Clinical Trials

New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA)

AURORA
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The role of neoadjuvant chemotherapy (NAC) in breast cancer is well established. Increasing rates of pathologic complete response (pCR) has increased de-escalation of surgical techniques. The objective of the study is to evaluate new radiologic techniques that can accurately detect complete response in order to eliminate breast surgery. . . Currently, there are several imaging techniques for NAC response assessment (magnetic resonance imaging -MRI-, mammography and ultrasound), with good correlation in partial response, but they lack power in predicting complete pathological response. The investigators propose to use IVIM (Intravoxel incoherent motion), Kurtosis (DKI by Diffusion Kurtosis imaging) and diffusion tensor image (DTI) in MRI, contrast enhancement mammography and shear wave elastography for the evaluation of the response to systemic treatment in breast cancer patients. In order to validate the technique, in those patients with a radiological complete response by all the radiological imaging methods, a vacuum-assisted biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen. So the investigators can evaluate if patients with complete radiological response after NAC, can be spared breast surgery.

NCT ID: NCT04794816 Recruiting - Breast Carcinoma Clinical Trials

What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care

Start date: January 21, 2021
Phase:
Study type: Observational

This study explores why patients may want to receive real-time imaging results during a screening mammogram appointment at an MD Anderson breast imaging center. Real-time imaging results means women receive the results of the mammogram right away during the same clinic visit. Information from this study may help researchers better understand patient preferences to enhance patient-experience driven care.

NCT ID: NCT04794075 Recruiting - Neoplasm of Breast Clinical Trials

Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer

ETAPH
Start date: August 9, 2021
Phase: N/A
Study type: Interventional

To compare the efficacy of the addition of a therapeutic education program combined with nursing phone follow-up, compared to conventional management alone, on the management of adverse events (AEs) related to adjuvant hormone therapy during the first year of treatment in patients with non-metastatic breast cancer.

NCT ID: NCT04792840 Not yet recruiting - Breast Cancer Clinical Trials

Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer

Start date: December 1, 2021
Phase:
Study type: Observational [Patient Registry]

study of lymphedema and skeletal events in breast cacer patient receiving adjuvant hormonal therapy and radiothearpy

NCT ID: NCT04792346 Completed - Breast Cancer Clinical Trials

Ten Fraction Adjuvant Hypofractionated Radiotherapy in Node Positive Breast Cancer

HIPOMAMMLINF
Start date: January 1, 2015
Phase:
Study type: Observational

Post-operative loco-regional (LR) hypofractionated radiotherapy (Hypo-RT) is an attractive approach in locally advanced breast cancer (LABC).

NCT ID: NCT04791384 Recruiting - Breast Cancer Clinical Trials

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Start date: April 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-institutional, single arm, open label, Phase Ib/II study of abemaciclib in combination with elacestrant in patients with HR+/Her2- breast cancer metastatic to the brain. Patients may have received up to two prior lines of systemic chemotherapy for locally advanced or metastatic disease. There will be no limit on prior use of endocrine therapy including aromatase inhibitors, tamoxifen and fulvestrant, given a documented clinical benefit of elacestrant in this setting.

NCT ID: NCT04790305 Recruiting - Clinical trials for Triple-negative Breast Cancer

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Start date: June 18, 2021
Phase: Phase 4
Study type: Interventional

This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.